Iron deficiency (ID), often associated with iron deficiency anemia (IDA), is one of the most significant dietary disorders, affecting approximately one-third of the population. Those at high risk of ID include the elderly, children, and women, particularly during menstruation and pregnancy.
Image Credit: PharmaNutra Spa
Recently, ID and IDA have been widely researched in patients with acute and chronic heart failure, with records indicating an average of 50%.
The disorder (ID) is characterized by a low level of iron in the body, and if a recovery is not made, it advances to an anemic clinical condition. Alternatively, IDA arises when the body is unable to fulfill proper hemoglobin production, which is vital to enable adequate oxygenation of cells and tissues within the body.
According to WHO recommendations, the accepted values for hemoglobin are:
| . |
. |
| Man |
≥ 130 g/dL |
| Woman |
≥ 120 g/dL |
| Children |
≥ 110 g/dL |
IDA is diagnosed in cases where hemoglobin values are less than those specified. Frequently, ID and IDA are treated with oral iron salts, despite poor absorption by the body and causing gastrointestinal side effects. As a result, there is decreased compliance and frequent drop-outs by patients.
Sucrosomial® Iron is a novel oral iron formulation in which ferric pyrophosphate is protected by a matrix of phospholipids and sucrose esters of fatty acids (Sucrosome®). The novelty of Sucrosomial® technology is characterized by exceptional tolerability, allowing iron intake at any time (with a meal or far from meals) for extended periods of time.
This helps prevent any discomfort typically linked to iron intake, such as irritation of the gastric mucosa, an unpleasant and metallic aftertaste, constipation or nausea.
Overcoming the constraints of conventional iron supplementation, Sucrosomial® iron supports the intake of this essential nutrient in all circumstances of deficiency or increased iron needs.
Image Credit: PharmaNutra Spa
Much scientific evidence within the field of cardiology has revealed that SiderAL® shows efficacy and holds a high tolerability profile in patients experiencing cardiological diseases. This demonstrates that Sucrosomial® Iron may be a feasible alternative for iron deficiency recovery, even following cardiac surgery, whereas this iron source is administered orally.
Image Credit: PharmaNutra Spa
It is crucial to note that an iron deficiency may cause a low quality of life and prolonged rehabilitation following surgery.
In conclusion, it is essential to assess preventive iron supplementation in all patients undergoing surgery to improve clinical outcomes and the patient’s quality of life.
References and further reading
- Nutritional anaemias: tools for effective prevention and control (2017). www.who.int
- S. Gómez-Ramírez, E. Brilli, G. Tarantino, M. Muñoz. (2018) Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation. Pharmaceuticals (Basel), 11(4), p. 97.
- R.J. Stoltzfus, (2001) Defining iron-deficiency anemia in public health terms: time for reflection, J. Nutr. 131, pp. 565S–S567.
- S. von Haehling, N. Ebner, R. Evertz, P. Ponikowski, S.D. Anker, (2019) Iron Deficiency in Heart Failure: An Overview, JACC Heart Fail 7(1) pp. 36–46.
- Cohen-Solal A, Damy T, Terbah M, et al. (2014) High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail., 16, pp. 984-991.
- J.G.F. Cleland, J. Zhang, P. Pellicori, B. Dicken, R. Dierckx, A. Shoaib, K. Wong, A. Rigby, K. Goode, A.L. Clark, (2016) Prevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure, JAMA Cardiol., 1(5), p. 539.
- Venturini E., et al. (2022) “Short-Term Treatment of Iron Deficiency Anemia After Cardiac Surgery”. Int J Cardiol Heart Vasc. 40, p. 101038.
- Karavidas A., et al. (2021) “Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non-randomized, open-label, proof-of-concept study” Eur J Heart Fail. 23(4), pp. 593-597.
About PharmaNutra S.p.A.
Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003.
It develops unique nutritional supplements and innovative medical devices, handling the entire production process, from proprietary raw materials to the finished product.
The effectiveness of its products is documented by considerable scientific proof, including 112 publications.
The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 150 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 39 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology.
Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.
PharmaNutra.it
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.